AIM ImmunoTech (AIM) Shares Outstanding (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Shares Outstanding (Entity) came in at $4.4 million in Q1 2026, up 501.94% YoY from $722900.0 in Q1 2025, and up 168.84% on a QoQ basis from $1.6 million in Q4 2025.
AIM ImmunoTech (AIM) Shares Outstanding (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Shares Outstanding (Entity) data on file, last reported at $4.4 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 501.94% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.4 million (up 501.94% YoY) and the FY2025 annual result came in at $1.6 million, up 147.02% from the prior year.
- Shares Outstanding (Entity) climbed to $4.4 million in Q1 2026, from $1.6 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $4.4 million in Q1 2026 to a low of $479947.0 in Q1 2022.
- A 5-year average of $925635.5 and a median of $502519.0 in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2022 — Shares Outstanding (Entity) slumped 99.9% — and 2026, when it surged 501.94%.
- Tracing AIM's Shares Outstanding (Entity) over 5 years: stood at $480843.0 in 2022, then gained by 2.12% to $491025.0 in 2023, then surged by 33.45% to $655263.0 in 2024, then jumped by 147.02% to $1.6 million in 2025, then soared by 168.84% to $4.4 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $4.4 million (Q1 2026), $1.6 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 133.61 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 217.35 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 445.06 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 241.70 Mn |
| 10 | AIM ImmunoTech | 4.34 Mn | -5.62 Mn | 21,000.00 | 17.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 17.12 Mn |
| Mar 31, 2026 | 4.35 Mn |
| Dec 31, 2025 | 1.62 Mn |
| Sep 30, 2025 | 2.09 Mn |
| Jun 30, 2025 | 759,289.00 |
| Mar 31, 2025 | 703,299.00 |
| Dec 31, 2024 | 560,169.00 |
| Sep 30, 2024 | 576,770.00 |
| Jun 30, 2024 | 528,375.00 |
| Mar 31, 2024 | 494,580.00 |
| Dec 31, 2023 | 485,854.00 |
| Sep 30, 2023 | 486,352.00 |
| Jun 30, 2023 | 484,113.00 |
| Mar 31, 2023 | 484,000.00 |
| Dec 31, 2022 | 480,473.00 |
| Sep 30, 2022 | 480,792.00 |
| Jun 30, 2022 | 480,341.00 |
| Mar 31, 2022 | 479,947.00 |
| Dec 31, 2021 | 473,400.00 |
| Sep 30, 2021 | 478.46 Mn |